Results 11 to 20 of about 5,281 (192)

Immunology and efficacy of MF59-adjuvanted vaccines [PDF]

Human Vaccines & Immunotherapeutics, 2018
Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries.
Eun-Ju Ko, Sang-Moo Kang
doaj   +4 more sources

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination [PDF]

npj Vaccines, 2022
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination ...
Johannes B. Goll, Aarti Jain, Travis L. Jensen, Rafael Assis, Rie Nakajima, Algis Jasinskas, Lynda Coughlan, Sami R. Cherikh, Casey E. Gelber, S. Khan, D. Huw Davies, Philip Meade, Daniel Stadlbauer, Shirin Strohmeier, Florian Krammer, Wilbur H. Chen, Philip L. Felgner   +16 more
doaj   +7 more sources

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. [PDF]

PLoS ONE, 2014
In an open label clinical study (2007), MF59-adjuvanted hemagglutinin (HA) vaccine from H5N1-A/Vietnam/1194/2004 (clade 1) was administered to subjects previously vaccinated (primed) with clade 0 H5N3 (A/duck/Singapore/97) vaccine at least 6 years ...
Surender Khurana, Elizabeth M Coyle, Milena Dimitrova, Flora Castellino, Karl Nicholson, Giuseppe Del Giudice, Hana Golding   +6 more
doaj   +6 more sources

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. [PDF]

PLoS ONE, 2017
MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an ...
Rossella Cioncada, Marcella Maddaluno, Hoa Thi My Vo, Matthew Woodruff, Simona Tavarini, Chiara Sammicheli, Marco Tortoli, Alfredo Pezzicoli, Ennio De Gregorio, Michael C Carroll, Ugo D'Oro, Diego Piccioli   +11 more
doaj   +2 more sources

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

Immunity & Ageing, 2008
Background The safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine (Sub/MF59™; FLUAD®, Novartis Vaccines) was evaluated among elderly Chinese subjects (≥ 60 years of age).
Pellegrini Michele, Liu Youping, Li Yanping, Fang Hanhua, Li Rongcheng, Podda Audino   +5 more
doaj   +2 more sources

AS03- and MF59-Adjuvanted Influenza Vaccines in Children [PDF]

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Bali Pulendran, Bali Pulendran, Bali Pulendran, Claire-Anne Siegrist, Andrew J. Pollard   +9 more
doaj   +5 more sources

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

PLoS Medicine
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen ...
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team   +33 more
doaj   +2 more sources

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

Vaccines
The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these ...
Kangwei Xu, Jing Li, Xu Lu, Xiaoqin Ge, Kaiqin Wang, Jiahao Wang, Zhizhong Qiao, Yaru Quan, Changgui Li   +8 more
doaj   +2 more sources

Formulation of hepatitis B vaccine in MF59 adjuvant and comparison of its immunization with Iran\'s commercial hepatitis B vaccine

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2018
Introduction: Hepatitis is a systemic diseasethat causes liver inflammation. The prevention of this infection is a vaccination. The commonly used vaccine to fight this disease is to use the vaccine formulated with Alum. This vaccine cannot provide immune
Reyhaneh Mirzaei, Fahimeh Nemati mansour, mehdi mahdavi   +2 more
doaj   +1 more source

From injection to inhalation: A STING-activating mucosal adjuvant reprograms vaccination. [PDF]

Clin Transl Med
Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Wang W, Wang M, Lu L, Jiang S, Liu Z.
europepmc   +2 more sources